Heart failure & cardiomyopathies

A 20-year population study of peripartum cardiomyopathy

Eur Heart JPublished Retrospective population-based cohort study

Authors' conclusion

PPCM affected 1 in 4950 women around the time of pregnancy. The condition is associated with considerable morbidity and mortality for the mother and child.

Study context

Population
Validated cases of peripartum cardiomyopathy in Scotland, 1998–2017women with PPCM
Participants
225 cases
Exposure
Women with PPCM vs matched controls
  • PPCMn = 225
Outcome
Incidence of PPCM
Methodological detailsobservational, population-level, matched controls (1:10)
  • Observational
  • Population-level
  • Matched controls (1:10)

Main finding

As reported in the abstract

PPCM

1 in 4950 deliveries

Observational data: associations, not effects.

Further findings

OutcomePPCM
All-cause death and any-cause rehospitalization (≥1) · median 8.3 years
Died8%
Rehospitalized for any cause at least once75%
All-cause death and any-cause rehospitalization (≥1) — Mortality rate in PPCM vs controls
∼12-times
All-cause death and any-cause rehospitalization (≥1) — Rehospitalization rate in PPCM vs controls
∼3-times

Risk factors for PPCM

Obesity, gestational hypertensive disorders and multi-gestation associated with PPCM

Composite of all-cause death, mechanical circulatory support or cardiac transplantation

Composite occurred
14%

LV recovery · median 9.7 years (echocardiographic outcomes)

LV recovery
76%
Decline in LV systolic function after initial recovery (of those recovered)
13%

Children born to women with PPCM vs children of controls · median 8.8 years

Mortality rate vs children of controls
∼5-times
Incidence of CVD vs children of controls
∼3-times greater

Original publication

A 20-year population study of peripartum cardiomyopathy. Eur Heart J. Published 7 October 2023. doi:10.1093/eurheartj/ehad626

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.